An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Bristol-Myers Squibb (BMS)

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Cancer

Treatments

Drug: BMS-986242

Biological: Nivolumab

Study type

Interventional

Funder types

Industry

Identifiers

CA024-001

2017-003603-21 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

Enrollment

7 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1
Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Ability to swallow tablets
Adequate bone marrow and organ function, as defined by the protocol

Exclusion Criteria:

Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)
Ocular melanoma
Any significant acute or chronic medical illness
Prior malignancy
Other active malignancy requiring concurrent intervention
Prior organ allograft or allogeneic bone marrow transplantation
Participants with active, known, or suspected autoimmune disease
Requirement for daily supplemental oxygen
Uncontrolled or significant cardiovascular disease
Pre-existing liver disease
Gastrointestinal disease known to interfere with absorption